<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997191</url>
  </required_header>
  <id_info>
    <org_study_id>6826/2009</org_study_id>
    <nct_id>NCT00997191</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)</brief_title>
  <acronym>IBeTA</acronym>
  <official_title>Intravitreal Bevacizumab and Intravitreal Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravitreal triamcinolone has been effective for central macular thickness reduction and
      concomitant visual acuity improvement in patients with diabetic macular edema (DME). VEGF is
      a very effective inducer of permeability, being 50.000 times more potent than histamine, and
      may exert its effect on retinal vascular permeability by altering tight-junctions proteins,
      such as occluding and VE-cadherin. Based on these principles, there is a rationale for
      anti-VEGF agents treatment of increased retinal capillary permeability conditions, such as
      diabetic macular edema. Therefore, the purpose of this study is to evaluate the effects of
      intravitreal bevacizumab and intravitreal triamcinolone associated to laser photocoagulation
      for diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Macular edema is a leading cause of decreased visual acuity in patients with diabetic
      retinopathy1,2.

      Laser photocoagulation is the standard of care treatment for diabetic macular edema, based on
      ETDRS and recent clinical trials findings3,4. However, because visual acuity improvement
      post-laser is observed infrequently, and because of the frequent recurrence or persistence of
      DME (refractory DME) after appropriate laser treatment, particularly in eyes presenting with
      angiographically diffuse macular edema5-9, there is a need for alternative treatments for the
      management of DME. In addition, for some patients with significant cataract, precise
      visualization of posterior pole structures may not be possible, so that pharmacological
      therapy with intravitreal agents may be preferable over laser treatment.

      Recent studies have shown promising results of pharmacological therapies for Diabetic macular
      edema. Triamcinolone has shown similar results when compared to ranibizumab and deferred
      focal/grid LASER in pseudophakic eyes (DRCRnet, prompt versus deferred). Ranibizumab
      associated with deferred LASER or as monotherapy has also shown promising results (RISE and
      RIDE). However, there are several concerns regarding long-term intravitreal injections
      therapies that include economic feasibility for the public health system, risk of
      endophthalmitis and patient acceptability. For these reasons, the present study decided to
      check associations between LASER and drug therapy, in an attempt to improve focal/grid laser
      outcomes with reduced number of intravitreal injections.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual acuity</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular Mapping Test</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multifocal Electroretinogram</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Macular Thickness</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Laser Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Focal / grid Laser photocoagulation in diabetic macular edema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <description>Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines</description>
    <arm_group_label>Laser Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal triamcinolone</intervention_name>
    <description>Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT&gt;275um</description>
    <arm_group_label>Triamcinolone group</arm_group_label>
    <other_name>Triancinolona (Ophthalmos)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal bevacizumab</intervention_name>
    <description>Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT&gt;275um</description>
    <arm_group_label>Bevacizumab group</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically significant DME - by biomicroscopic evaluation with generalized breakdown
             of the inner blood-retina barrier with diffuse fluorescein leakage involving the
             foveal center and most of the macular area on fluorescein angiography

          -  Snellen logarithm of minimum angle of 20/40 or worse

          -  Central macular thickness greater than 275 µm on optical coherence tomography (OCT)

        Exclusion Criteria:

          -  Glycosylated hemoglobin rate above 10%

          -  History of glaucoma or ocular hypertension

          -  Systemic corticoid therapy

          -  History of thromboembolic event (including myocardial infarction or cerebral vascular
             accident)

          -  Major surgery within the prior 6 months or planned within the next 28 days

          -  Uncontrolled hypertension

          -  Severe systemic disease

          -  Any condition affecting documentation or follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria L Paccola, MD</last_name>
    <role>Study Chair</role>
    <affiliation>HC FMRP - USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>André M V Messias, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>HCFMRP - USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bianka Y N Y Katayama, MD</last_name>
    <role>Study Director</role>
    <affiliation>HC FMRP - USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo Jorge, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HC FMRP - USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rogério A Costa, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>HC FMRP - USP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008 Jan;92(1):76-80. Epub 2007 Oct 26.</citation>
    <PMID>17965109</PMID>
  </reference>
  <reference>
    <citation>Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3845-9.</citation>
    <PMID>16186372</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.</citation>
    <PMID>2866759</PMID>
  </reference>
  <reference>
    <citation>Garner A. Pathology of diabetic retinopathy. Br Med Bull. 1970 May;26(2):137-42. Review.</citation>
    <PMID>4192644</PMID>
  </reference>
  <reference>
    <citation>Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):766-85.</citation>
    <PMID>2062512</PMID>
  </reference>
  <reference>
    <citation>Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006 Nov-Dec;26(9):1006-13.</citation>
    <PMID>17151487</PMID>
  </reference>
  <reference>
    <citation>Jonas JB, Kreissig I, Söfker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003 Jan;121(1):57-61.</citation>
    <PMID>12523885</PMID>
  </reference>
  <reference>
    <citation>Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991 Oct;98(10):1594-602.</citation>
    <PMID>1961650</PMID>
  </reference>
  <reference>
    <citation>Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006 May;124(5):653-8.</citation>
    <PMID>16682586</PMID>
  </reference>
  <reference>
    <citation>Karacorlu M, Ozdemir H, Senturk F, Arf Karacorlu S, Uysal O. Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur J Ophthalmol. 2008 Jul-Aug;18(4):601-8.</citation>
    <PMID>18609482</PMID>
  </reference>
  <reference>
    <citation>Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002 May;109(5):920-7.</citation>
    <PMID>11986098</PMID>
  </reference>
  <reference>
    <citation>Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008 Oct;28(8):1053-60. doi: 10.1097/IAE.0b013e318176de48.</citation>
    <PMID>18779710</PMID>
  </reference>
  <reference>
    <citation>Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005 May;139(5):802-6.</citation>
    <PMID>15860283</PMID>
  </reference>
  <reference>
    <citation>Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Tabatabaei H, Peyman GA. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007 Nov-Dec;27(9):1187-95.</citation>
    <PMID>18046223</PMID>
  </reference>
  <reference>
    <citation>Vujosevic S, Pilotto E, Bottega E, Benetti E, Cavarzeran F, Midena E. Retinal fixation impairment in diabetic macular edema. Retina. 2008 Nov-Dec;28(10):1443-50. doi: 10.1097/IAE.0b013e318183571e.</citation>
    <PMID>18997608</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>February 28, 2013</last_update_submitted>
  <last_update_submitted_qc>February 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Rodrigo Jorge</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Intravitreal</keyword>
  <keyword>Macular edema</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

